Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: 2MAR$ who wrote (879)	6/23/2001 11:28:39 AM
From: DebtBomb	Respond to of 208838

Stocks: Get In, Get Out or Get Smart? biz.yahoo.com

To: 2MAR$ who wrote (879)	6/24/2001 10:54:48 AM
From: keithcray	Read Replies (1) \| Respond to of 208838

Biotech Meeting Attracts Protesters Sunday, June 24, 2001 By Justin Gillis, Washington Post Staff Writer As many as 15,000 scientists and business executives are gathering in San Diego today for the nation's largest-ever conference on biotechnology — and are being met by an army of protesters determined to confront what they see as a corporate agenda to control "our bodies, our futures, our food." Merchants in downtown San Diego fear violence like that in Seattle in 1999 that shut down a world trade conference. Some of the same groups that demonstrated in Seattle are showing up this week. Some San Diego merchants are closing for the first part of the week. A few plan to board up their stores, and a heavy police presence is expected on downtown streets until the conference ends on Wednesday. "We do expect more problems this year — how many, we won't know until it happens," said Dan Eramian, chief spokesman for the Biotechnology Industry Organization. "Kids have a right to protest, and we have a right to hold our meeting." The annual convention of the BIO, based in Washington, has been growing rapidly in recent years as the industry expands its research, using genetic information to study disease and to develop new drugs, foods and industrial products. From 12,000 to 15,000 registrants are expected at the San Diego convention, three times what the BIO drew just four years ago. The BIO convention has been accompanied by protests for several years. Last year in Boston, 2,000 protesters spent an afternoon attacking biotechnology with speeches, marches and songs. Many of those protesters appeared to object most strongly to genetic manipulation of food crops, whereas most of the researchers at the convention were involved in work on human health. This produced the incongruous situation of protesters yelling epithets like "murderer" and "pirate" at people looking for ways to treat diseases such as cancer and AIDS. The protesters in San Diego are calling their street demonstrations, scheduled over all four days of the convention, "Biojustice Days of Action." The movement is backed by a loose coalition of groups with varying political positions. Some object most strongly to genetically engineered food, others to the patenting of genetic information, and still others to the global spread of capitalism. Some of the same groups held largely peaceful street demonstrations in Washington last year against the World Bank and the International Monetary Fund. Adam Hurtler, a Connecticut college student and spokesman for the campaign, said organizers cannot control individual protesters, but the prospect of violence in San Diego has been overstated by the BIO and the police to deflect attention from substantive issues. "The real violence being done here is being done every day by these corporations up in their ivory towers," he said. "The biotech industry is seizing control over our bodies, our futures, our food. . . . We have enough food. We have enough medicine. The real roots of the global health crisis are inequality and injustice, and that's what the biotech industry is perpetuating." Carl Feldbaum, president of BIO, acknowledged that biotechnology advances pose real issues worth debating — he named access to drugs and the fear of genetic discrimination as being among them — but said the technology offers promise for solving some of mankind's oldest problems, including disease and hunger. "Some of the protest groups know absolutely nothing about biotechnology," he said. Assuming it is not disrupted by the protests, the BIO convention is expected to include scores of presentations, talks and panel discussions on the latest scientific research and financial news in the industry. Two Washington area scientists are expected to receive an award for their sometimes-friendly, sometimes-competitive roles in helping to unravel the human genetic map, the genome. The scientists are Francis Collins, director of the National Human Genome Research Institute in Bethesda, and Craig Venter, president and chief scientific officer of Celera Genomics Corp. of Rockville. The two scientists headed rival teams that raced to a draw last year in producing the genome maps, then simultaneously published detailed scientific papers in February. The implications of that work are expected to be the No. 1 topic of discussion at the convention. © 2001 The Washington Post Company

To: 2MAR$ who wrote (879)	6/24/2001 11:44:02 AM
From: keithcray	Respond to of 208838

Inktomi Receives Dell’s Endorsement by Elyssa Jaffe 1:45:00 PM June 22, 2001 GMT Leading PC maker Dell Computer [DELL:Nasdaq] will soon announce that it has closed a deal with Internet software company Inktomi [INKT:Nasdaq]. The deal is a key win for Inktomi, due to the increased visibility the endorsement offers. Despite the news, we continue to rate shares of Inktomi a Sell. Dell will offer the software for systems that process web pages. The hardware and software combination will be sold as caching appliances, which are used to store frequently used web pages for quick retrieval. The caching appliances offer the scalability and efficiency companies need to handle varying demand loads. The infrastructure is better managed and easier to use for Internet searching. The addition of Dell to its reseller list serves as a strong show of support for Inktomi. Other top-notch customers currently include Hewlett-Packard [HWP:NYSE] and Compaq Computer [CPQ:NYSE]. Inktomi is working hard to recover the business it lost from the dot.com shakeout during the last year. Unfortunately, replacement business is slow in coming. Earlier this year, the company was forced to cut 25% of its work force, causing a charge to earnings in its upcoming quarter. As for the fiscal Q3, results for which are due July 19, they too will be lower than originally forecast. Revenues are expected to range between $38m-$40m, with a per-share loss of $0.16-$0.17. Management believes the turbulence will be short-lived, and information-technology budgets will firm toward the end of 2001. But with cash dwindling, the company closed out last quarter with approximately $271m in cash. We anticipate further downside, as increased uneasiness among investors builds.